Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

"BRI overcomes the CAS-acquired resistance in both A. fumigatus
and C. albicans and the CAS-intrinsic resistance in C. neoformans. BRI also
has an additive effect on the activity of posaconazole (POSA) against several
Mucorales fungi. Cell toxicity assays and fungal burden studies in an
immunosuppressed murine model of IPA showed that BRI combined with CAS
is not toxic to the cells and significantly clears A. fumigatus lung infection,
respectively. Our results indicate that combinations of BRI and antifungal drugs
in clinical use are likely to improve the treatment outcome of IPA and other
fungal infections".

I think this is a no brainer as an inhaler for hospital use. Fungal infections are a problem in hospitals.